| 0.0799 0.044 (121.94%) | 06-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.21 | 1-year : | 0.35 |
| Resists | First : | 0.18 | Second : | 0.3 |
| Pivot price | 0.01 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.01 | MA(20) : | 0.02 |
| MA(100) : | 0.23 |
MA(250) : | 0.82 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 11.8 |
| RSI | RSI(14): 27.9 | |||
| 52-week | High : | 2.44 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NOTV ] has closed above bottom band by 40.9%. Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Mon, 20 Jul 2026
Inotiv’s Existing Stakeholders Provide Capital as Chapter 11 Ends - Stock Titan
Tue, 14 Jul 2026
Inotiv Expects Chapter 11 Exit Shortly After Plan Approval - Stock Titan
Thu, 11 Jun 2026
New Options Listings and Delistings for Inotiv, Inc. (NOTV) - GuruFocus
Sun, 07 Jun 2026
The Inotiv Prepack: Deleveraging a Contract Research Platform Through a Consensual Plan - chapter11cases.com
Thu, 04 Jun 2026
Case Summary: Inotiv Chapter 11 - Bondoro
Wed, 03 Jun 2026
Inotiv files for bankruptcy in Texas (NOTV:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 35 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 8.6 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 2,520 (K) |
| Shares Short P.Month | 3,130 (K) |
| EPS | -2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | -17.2 % |
| Operating Margin | -16.1 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | -74.1 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 3.33 |
| Sales Per Share | 14.54 |
| EBITDA (p.s.) | 0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|